Jamin Brown, MD
Retina Specialist · Liverpool, NYNPI 1235242124
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (46.8%), ownership interests and travel and lodging — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 80.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $10,866 and has fallen 97.1% since, to $318 in 2025.
Across 26 payments — averaging $682.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$14K
- Dutch Ophthalmic, USA$2K
- Alcon$244
- Ocular Therapeutix, Inc.$198
- Astellas Pharma US Inc$149
- Amgen$125
- plus $352 from 6 others
Across 439 payments — averaging $7436.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.6M
- Novartis$568K
- Regeneron$283K
- Amgen$214K
- Kyowa Kirin, Inc.$201K
- Janssen Research & Development, LLC$163K
- plus $231K from 5 others
What the payments were for
- Consulting fees$1,0006%
- Travel & lodging$1,2747%
- Food & beverage$1,1717%
- Ownership interest$5,99234%
- Other$8,31547%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $14,307 |
| Dutch Ophthalmic, USA | 4 | $2,377 |
| Alcon | 2 | $244 |
| Ocular Therapeutix, Inc. | 2 | $198 |
| Astellas Pharma US Inc | 3 | $149 |
| Amgen | 1 | $125 |
| Novartis | 1 | $122 |
| Tearlab Corp | 1 | $77 |
| Regeneron Healthcare Solutions, Inc. | 2 | $61 |
| Genentech, Inc. | 1 | $59 |
| AbbVie | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVA, combined machine$2,274
- TISSUEBLUE$2,274
- Unity$133
- TEPEZZA$125
- BUPARLISIB$122
- Clareon$111
How this compares
$17,751 in reported general payments places this provider in the 85th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 259 | $10,192 |
| Bromfenac Sodium | 26 | $3,225 |
| Difluprednate | 18 | $2,013 |
| Ketorolac Tromethamine | 104 | $1,628 |
| Timolol Maleate | 116 | $1,552 |
| Brimonidine Tartrate | 28 | $1,097 |
| Latanoprost | 95 | $913 |
| Tobramycin | 154 | $753 |
| Acetazolamide | 12 | $236 |
| Diclofenac Sodium | 19 | $169 |
| ValacyclovirValacyclovir Hcl | 12 | $161 |
| ErythromycinErythromycin Base | 14 | $137 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Liverpool
- Mark BreazzanoLiverpool$30K
- Patrick OellersLiverpool$17K
- Bryan RutledgeLiverpool$15K
- Samuel SpaldingLiverpool$15K
- Rajeev SethLiverpool$14K
- Kevin RosenbergLiverpool$14K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.